Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 16/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 15/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.32 |
| ▸ | TESK1 | Q15569 | 2/20 | 0.32 |
| ▸ | TESK2 | Q96S53 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018434 | 1.00 | LIMK1 (0.38) | LIMK1LIMK2MAPK14LATS1LATS2 | |
| SCHEMBL4019003 | 1.00 | LIMK1 (0.38) | LIMK1LIMK2MAPK14LATS1LATS2 | |
| SCHEMBL16989331 | 0.89 | LIMK1 (0.36) | LIMK1LIMK2MAPK14LATS1LATS2 | |
| SCHEMBL13870027 | 0.89 | LIMK1 (0.36) | LIMK1LIMK2MAPK14LATS1LATS2 | |
| SCHEMBL15626293 | 0.89 | LIMK1 (0.36) | LIMK1LIMK2MAPK14LATS1LATS2 | |
| Hydrochloric Acid SCHEMBL4017653 | 0.89 | HRH3 (0.38) | LIMK1MAPK14 | |
| SCHEMBL5748048 | 0.89 | LIMK1 (0.38) | LIMK1LIMK2MAPK14TESK1TESK2 | |
| SCHEMBL4017219 | 0.88 | HRH3 (0.39) | LIMK1MAPK14 | |
| SCHEMBL4016503 | 0.88 | HRH3 (0.39) | LIMK1MAPK14 | |
| SCHEMBL4017130 | 0.88 | HRH3 (0.39) | LIMK1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663241-B1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2009-05-27 | — | — | EP | claimed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | claimed |
| US-7501423-B2 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2009-03-10 | — | — | US | claimed |
| EP-1891052-A1 | TUBULIN INHIBITOR AND PROCESS FOR ITS PREPARATION | Wyeth (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070249627-A1 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2007-10-25 | — | — | US | claimed |
| US-7244736-B2 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2007-07-17 | — | — | US | claimed |
| WO-2006138180-A1 | TUBULIN INHIBITOR AND PROCESS FOR ITS PREPARATION | WYETH (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2006-12-14 | — | — | US | claimed |
| EP-1663241-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | claimed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | claimed |
| EP-1663241-B1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-7501423-B2 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501423-B2 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2009-03-10 | — | — | US | disclosed |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2006-12-14 | — | — | US | disclosed |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2006-12-14 | — | — | US | disclosed |
| EP-1663241-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249627-A1 | Tubulin inhibitor and process for its preparation | TUBB1, TUBB6, TUBB | LIMK1 2787/4885LIMK2 2344/4885MAPK14 2125/4885 |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | TUBB1, TUBB6, TUBB | LIMK1 2787/4885LIMK2 2344/4885MAPK14 2125/4885 |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | DPYD, ABCC1, ARF5 | LIMK1 2268/4885LIMK2 1660/4885MAPK14 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.